# Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers

> **NCT05806385** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Texas Tech University Health Sciences Center** · enrollment: 36 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DEVICE:** Cryoablation
- **COMBINATION_PRODUCT:** Cryoablation combined with PD1 Inhibitor

## Key facts

- **NCT ID:** NCT05806385
- **Lead sponsor:** Texas Tech University Health Sciences Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-01
- **Final completion:** 2029-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806385, "Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05806385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*